Abstract
Autoimmune Encephalitides (AE) comprises a group of diseases with antibodies against neuronal synaptic and cell surface antigens. Since the discovery of the most common subtype, NMethyl- D-Aspartate (NMDA) receptor encephalitis, an astonishing number of novel disease-causing antibodies have been described. This includes other glutamatergic and GABAergic receptor antibodies and antibodies against various other surface proteins. Many of these novel conditions present as limbic encephalitis with memory impairment, psychiatric features and epileptic seizures, often alongside subtype specific clinical features. Others present with a clinical disease course specific to the antibody. In contrast to the well-known paraneoplastic syndromes with antibodies directed against intracellular antigens (e.g. limbic encephalitis with Hu antibodies), autoimmune encephalitides are often highly responsive to immunotherapy, with a good outcome if diagnosed and treated early. Prognosis depends on aggressive immunotherapy, often with a combination of corticosteroids, intravenous immunoglobulin, plasma exchange or in some cases anti-CD20 therapy and cyclophosphamide. Other treatment regimens exist, and prognosis varies between disease subtypes and occurrence of underlying cancer. We review current knowledge on subtype-specific clinical presentation, disease mechanisms, diagnosis including pitfalls, treatment paradigms and outcome in autoimmune encephalitides, and provide suggestions for future research.
Keywords: Autoimmune, encephalitis, inflammation, antibodies, NMDA, treatment.
CNS & Neurological Disorders - Drug Targets
Title:Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment
Volume: 19 Issue: 8
Author(s): Mette Scheller Nissen, Matias Ryding, Morten Meyer and Morten Blaabjerg*
Affiliation:
- Department of Neurology, Odense University Hospital, J.B. Winsløwvej 29, DK-5000 Odense,Denmark
Keywords: Autoimmune, encephalitis, inflammation, antibodies, NMDA, treatment.
Abstract: Autoimmune Encephalitides (AE) comprises a group of diseases with antibodies against neuronal synaptic and cell surface antigens. Since the discovery of the most common subtype, NMethyl- D-Aspartate (NMDA) receptor encephalitis, an astonishing number of novel disease-causing antibodies have been described. This includes other glutamatergic and GABAergic receptor antibodies and antibodies against various other surface proteins. Many of these novel conditions present as limbic encephalitis with memory impairment, psychiatric features and epileptic seizures, often alongside subtype specific clinical features. Others present with a clinical disease course specific to the antibody. In contrast to the well-known paraneoplastic syndromes with antibodies directed against intracellular antigens (e.g. limbic encephalitis with Hu antibodies), autoimmune encephalitides are often highly responsive to immunotherapy, with a good outcome if diagnosed and treated early. Prognosis depends on aggressive immunotherapy, often with a combination of corticosteroids, intravenous immunoglobulin, plasma exchange or in some cases anti-CD20 therapy and cyclophosphamide. Other treatment regimens exist, and prognosis varies between disease subtypes and occurrence of underlying cancer. We review current knowledge on subtype-specific clinical presentation, disease mechanisms, diagnosis including pitfalls, treatment paradigms and outcome in autoimmune encephalitides, and provide suggestions for future research.
Export Options
About this article
Cite this article as:
Nissen Scheller Mette , Ryding Matias , Meyer Morten and Blaabjerg Morten *, Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment, CNS & Neurological Disorders - Drug Targets 2020; 19 (8) . https://dx.doi.org/10.2174/1871527319666200708133103
DOI https://dx.doi.org/10.2174/1871527319666200708133103 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Detailed Molecular Biochemistry for Novel Therapeutic Design Against Nipah and Hendra Virus: A Systematic Review
Current Molecular Pharmacology Potential of Alphavirus Vectors in the Treatment of Advanced Solid Tumors
Recent Patents on Anti-Cancer Drug Discovery Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Catatonia: A Narrative Review
Central Nervous System Agents in Medicinal Chemistry Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology New Drug Targets for Hepatitis C and Other Flaviviridae Viruses
Infectious Disorders - Drug Targets The Use of Lectins as Tools to Combat SARS-CoV-2
Current Pharmaceutical Design Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents Alzheimers Disease and Intelligence
Current Alzheimer Research Relation of Steatosis to Neurocognitive Function in People Living with HIV
Current HIV Research Pathogen-Related Signal Transduction Pathways of Dendritic Cells: Perspectives for Cancer Immunotherapy
Current Signal Transduction Therapy The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Picornavirus IRES: Structure Function Relationship
Current Pharmaceutical Design Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Radiotracers for Molecular Imaging of Cyclooxygenase-2 (COX-2) Enzyme
Current Medicinal Chemistry Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry